company background image
ALEC logo

Alector NasdaqGS:ALEC Voorraadrapport

Laatste prijs

US$5.02

Marktkapitalisatie

US$488.6m

7D

-1.0%

1Y

-8.2%

Bijgewerkt

04 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

Alector, Inc.

NasdaqGS:ALEC Voorraadrapport

Marktkapitalisatie: US$488.6m

ALEC Overzicht aandelen

Alector, Inc., een biofarmaceutisch bedrijf in een klinische fase, ontwikkelt therapieën voor de behandeling van neurodegeneratieziekten.

Alector, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Alector
Historische aandelenkoersen
Huidige aandelenkoersUS$5.02
52 Week HoogtepuntUS$8.90
52 Week LaagUS$3.66
Bèta0.68
11 maand verandering8.66%
3 maanden verandering-0.79%
1 Jaar Verandering-8.23%
33 jaar verandering-79.81%
5 jaar verandering-69.90%
Verandering sinds IPO-72.11%

Recent nieuws en updates

Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

Oct 24
Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

Sep 26
We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

Recent updates

Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

Oct 24
Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

Sep 26
We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Jul 11
Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11
Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01
Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Jan 19
The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Sep 25
Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Jun 27
Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Mar 02
Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Jan 16
Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Oct 04

AbbVie ends partnership with Alector for Alzheimer’s candidate

Jul 08

Alector: Potential In Neurology And Cancer Treatments

Jun 14

Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022

May 18
Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022

Alector: Expect Phase 3 Data Next Year

Apr 16

These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts

Feb 27
These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts

Alector, Inc: A Newer Biotech Company With Big Potential

Jan 26

Alector: The GSK Deal Is A Major Value Add

Oct 29

Rendement voor aandeelhouders

ALECUS BiotechsUS Markt
7D-1.0%-0.7%-1.6%
1Y-8.2%19.8%30.8%

Rendement versus industrie: ALEC underperformed the US Biotechs industry which returned 19.8% over the past year.

Rendement versus markt: ALEC underperformed the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is ALEC's price volatile compared to industry and market?
ALEC volatility
ALEC Average Weekly Movement10.2%
Biotechs Industry Average Movement9.6%
Market Average Movement6.0%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stabiele aandelenkoers: ALEC's share price has been volatile over the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: ALEC's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2013245Arnon Rosenthalwww.alector.com

Alector, Inc., een biofarmaceutisch bedrijf in een klinische fase, ontwikkelt therapieën voor de behandeling van neurodegeneratieziekten. Haar producten omvatten AL001, een immuunactiviteit in de hersenen met genetische verbanden met meerdere neurodegeneratieve aandoeningen, dat zich in Fase III van het klinisch onderzoek bevindt voor de behandeling van frontotemporale dementie, de ziekten van Alzheimer, Parkinson en amyotrofe laterale sclerose; en AL101 dat zich in Fase I van het klinisch onderzoek bevindt voor de behandeling van neurodegeneratieve ziekten, waaronder de ziekten van Alzheimer en Parkinson. Het bedrijf biedt ook AL002 aan, een kandidaat-product dat zich in Fase II van de klinische studie bevindt voor de behandeling van de ziekte van Alzheimer.

Alector, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Alector zich tot de beurswaarde?
ALEC fundamentele statistieken
MarktkapitalisatieUS$488.55m
Inkomsten(TTM)-US$160.66m
Inkomsten(TTM)US$55.28m

8.8x

P/S-verhouding

-3.0x

Koers/Winstverhouding

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ALEC resultatenrekening (TTM)
InkomstenUS$55.28m
Kosten van inkomstenUS$191.53m
Brutowinst-US$136.26m
Overige uitgavenUS$24.41m
Inkomsten-US$160.66m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-1.65
Brutomarge-246.51%
Nettowinstmarge-290.66%
Schuld/Eigen Vermogen Verhouding0%

Hoe presteerde ALEC op de lange termijn?

Bekijk historische prestaties en vergelijking